A new batch of strontium-89 (Sr-89) will be available through the DOE Isotope Program (DOE IP) in March 2020. The radioactive isotope is most commonly used in cancer therapy to relieve pain associated with cancer that has spread to the bone. Currently, the DOE IP is the only U.S. domestic supplier of strontium-89.
Strontium-89 (t1/2 = 50.563 days) is produced via neutron capture on an enriched strontium-88 oxide target using the DOE's High Flux Isotope Reactor, located at Oak Ridge National Laboratory. Following radiochemical processing, the product has a radionuclidic purity of >99.8% and is sold as strontium chloride solution in 0.1 N HCI.
For further inquiries about Sr-89, please contact the NIDC at contact@isotopes.gov or click the link below to request a quote.
